Eli Lilly said Wednesday that its experimental drug solanezumab failed to improve cognition of patients with mild Alzheimer's disease in a large phase III clinical trial.

If you liked this article you might like

5 New Breast Cancer Treatments That Are Helping to Save Lives
IBM CEO Ginni Rometty Rules Struggling Tech Giant, Aided by Entrenched Board Members
Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment
Cramer: 10 Reasons for Today's Rally